Aspirin use in people with established cardiovascular disease (CVD) is well founded; however, its use in primary prevention, even in high-risk populations, has never been proven beneficial. Despite the lack of evidence, many guidelines advocate the use of low-dose aspirin in older people with diabetes. This article reviews the literature on this topic, including the POPADAD (Prevention of Progression of Arterial Disease and Diabetes) study, published recently in the British Medical Journal. This prospective randomised trial addresses this issue in a UK-based population with diabetes and asymptomatic peripheral vascular disease. It provides further evidence that aspirin does not afford cardiovascular protection in the absence of proven symptomatic CVD.
|Number of pages||5|
|Journal||Diabetes and Primary Care|
|Publication status||Published - 7 Apr 2009|
- Cardiovascular disease
- Primary prevention